Related Experiment Video
Updated: Feb 21, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Ameliorative effect of gallic acid on doxorubicin-induced cardiac dysfunction in rats
Temiday O Omóbòwálé1, Ademola A Oyagbemi2, Ayorinde M Folasire3
1Department of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria.
Background:
The use of doxorubicin (DOX) as an antineoplastic agent has been greatly limited because of the myriad of toxic sequelae associated with it. The aim of this study was to assess the protective effects of gallic acid (GA) on DOX-induced cardiac toxicity in rats.
Methods:
Sixty male rats (Wistar strain) were used in this study. They were divided into six groups (A-F) each containing 10 animals. Group A was the control. Rats in Groups B, C, and D were treated with DOX at the dosage of 15 mg/kg body weight i.p. Prior to this treatment, rats in Groups C and D had been treated orally with GA for 7 days at the dosage of 60 and 120 mg/kg, respectively. Animals from Groups E and F received only 60 and 120 mg/kg GA, respectively, which were administered orally for 7 days.
Results:
The exposure of rats to DOX led to a significant (p<0.05) decrease in the cardiac antioxidant defence system and elevation of creatine kinase myocardial band and lactate dehydrogenase. The electrocardiography results showed a significant decrease in heart rate, QRS, and QT-segment prolongation. GA alone improved the antioxidant defence system.
Conclusions:
The GA pretreatment significantly alleviated GA-associated ECG abnormalities, restored the antioxidant status and prevented cardiac damage.
Insights
Gallic acid (GA) pretreatment protected rats against doxorubicin (DOX)-induced cardiotoxicity by restoring antioxidant status and preventing cardiac damage. GA supplementation improved ECG abnormalities and cardiac enzyme levels.
Area of Science:
- Cardiology
- Pharmacology
- Toxicology
Background:
- Doxorubicin (DOX) is an effective antineoplastic agent.
- DOX use is limited by severe cardiotoxicity.
- Investigating protective agents against DOX-induced cardiac damage is crucial.
Purpose of the Study:
- To evaluate the protective effects of gallic acid (GA) against doxorubicin (DOX)-induced cardiotoxicity in a rat model.
- To assess GA's impact on cardiac antioxidant status and function following DOX exposure.
Main Methods:
- Sixty male Wistar rats were divided into six groups.
- Groups received varying treatments of DOX and/or GA (60 or 120 mg/kg) orally for 7 days.
- Cardiac function was assessed via electrocardiography (ECG) and biochemical markers.
Main Results:
- DOX exposure significantly decreased cardiac antioxidant defense and elevated cardiac enzymes (CK-MB, LDH).
- DOX induced significant ECG abnormalities, including decreased heart rate and prolonged QRS/QT segments.
- GA alone improved the antioxidant defense system.
Conclusions:
- Gallic acid (GA) pretreatment significantly alleviated DOX-induced ECG abnormalities.
- GA restored the cardiac antioxidant status in rats exposed to DOX.
- GA demonstrated a protective effect against DOX-induced cardiac damage.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System